113 related articles for article (PubMed ID: 7978930)
1. Epidermal growth factor receptor expression and endometrial cancer histotypes.
Jasonni VM; Santini D; Amadori A; Ceccarelli C; Naldi S
Ann N Y Acad Sci; 1994 Sep; 734():298-305. PubMed ID: 7978930
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor (EGF-R) and transforming growth factor alpha (TGFA) expression in different endometrial cancers.
Jasonni VM; Amadori A; Santini D; Ceccarelli C; Naldi S; Flamigni C
Anticancer Res; 1995; 15(4):1327-32. PubMed ID: 7654016
[TBL] [Abstract][Full Text] [Related]
3. Immunocytochemical study of epidermal growth factor receptor, transforming growth factor alpha, and "squamous differentiation" in human endometrial carcinoma.
Santini D; Ceccarelli C; Martinelli GN; Leone O; Marabini A; Orlandi C; Mancini AM
Hum Pathol; 1994 Dec; 25(12):1319-23. PubMed ID: 7528164
[TBL] [Abstract][Full Text] [Related]
4. P16(INK4a) protein expression in endocervical, endometrial and metastatic adenocarcinomas of extra-uterine origin: diagnostic and clinical considerations.
Caponio MA; Addati T; Popescu O; Petroni S; Rubini V; Centrone M; Trojano G; Simone G
Cancer Biomark; 2014; 14(2-3):169-75. PubMed ID: 24878818
[TBL] [Abstract][Full Text] [Related]
5. Expression of epidermal growth factor receptors in human endometrial carcinoma.
Nyholm HC; Nielsen AL; Ottesen B
Int J Gynecol Pathol; 1993 Jul; 12(3):241-5. PubMed ID: 8344761
[TBL] [Abstract][Full Text] [Related]
6. Multidirectional differentiation of endometrial carcinoma with special reference to tumor aggressiveness evaluated by Ki-67 expression.
Ikawa S; Sano T; Furumoto H; Aono T
Gynecol Oncol; 1999 Mar; 72(3):323-30. PubMed ID: 10053102
[TBL] [Abstract][Full Text] [Related]
7. High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma.
McCluggage WG; Maxwell P; Hamilton PW; Jasani B
Histopathology; 1999 Jan; 34(1):51-5. PubMed ID: 9934584
[TBL] [Abstract][Full Text] [Related]
8. Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor.
Fujiwara S; Nawa A; Nakanishi T; Shimoyama Y; Kajiyama H; Shibata K; Ino K; Nakamura S; Kikkawa F; Yatabe Y
Hum Pathol; 2010 Apr; 41(4):560-5. PubMed ID: 20004952
[TBL] [Abstract][Full Text] [Related]
9. Endometrial carcinomas.
Dallenbach-Hellweg G
Curr Top Pathol; 1992; 85():1-34. PubMed ID: 1321020
[No Abstract] [Full Text] [Related]
10. Mucinous endometrial epithelial proliferations: a morphologic spectrum of changes with diverse clinical significance.
Nucci MR; Prasad CJ; Crum CP; Mutter GL
Mod Pathol; 1999 Dec; 12(12):1137-42. PubMed ID: 10619266
[TBL] [Abstract][Full Text] [Related]
11. [Expression of epidermal growth factor receptor and concentrations of epidermal growth factor and melatonin in endometrial carcinoma].
Dznelashvili N; Kasradze D; Tavartkiladze A
Georgian Med News; 2014 Oct; (235):17-24. PubMed ID: 25416211
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical study of estradiol, epidermal growth factor, transforming growth factor alpha and epidermal growth factor receptor in endometrial neoplasia.
Yokoyama Y; Takahashi Y; Hashimoto M; Morishita S; Tamaya T
Jpn J Clin Oncol; 1996 Dec; 26(6):411-6. PubMed ID: 9001345
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor in human breast cancer, endometrial carcinoma and lung cancer. Its relationship to epidermal growth factor receptor, estradiol receptor and tumor TNM.
Bolufer P; Lluch A; Molina R; Alberola V; Vazquez C; Padilla J; Garcia-Conde J; Llopis F; Guillem V
Clin Chim Acta; 1993 Apr; 215(1):51-61. PubMed ID: 8513568
[TBL] [Abstract][Full Text] [Related]
14. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Characteristics and
Sung JY; Jung YY; Kim HS
Anticancer Res; 2018 May; 38(5):2779-2786. PubMed ID: 29715099
[TBL] [Abstract][Full Text] [Related]
16. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.
González-Rodilla I; Aller L; Llorca J; Muñoz AB; Verna V; Estévez J; Schneider J
Anticancer Res; 2013 Nov; 33(11):5091-5. PubMed ID: 24222154
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic Ras modulates epidermal growth factor responsiveness in endometrial carcinomas.
Kato K; Ueoka Y; Kato K; Tamura T; Nishida J; Wake N
Eur J Cancer; 1998 Apr; 34(5):737-44. PubMed ID: 9713283
[TBL] [Abstract][Full Text] [Related]
18. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
19. Atypical mucinous glandular proliferations in endometrial samplings: follow-up and other clinicopathological findings in 41 cases.
Rawish KR; Desouki MM; Fadare O
Hum Pathol; 2017 May; 63():53-62. PubMed ID: 28232161
[TBL] [Abstract][Full Text] [Related]
20. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
